
Bayer’s share price has exploded higher in early December 2025 after the U.S. government unexpectedly sided with the company in its long‑running Roundup legal saga. For investors in Bayer Aktie, the move has transformed sentiment almost overnight – but the underlying story is still a complex mix of litigation risk, heavy debt, restructuring and a slowly improving pipeline.
Today’s highest-ranked model selections.